Dualderm Galacvita C Auto Eye Cream

These describe what an ingredient is, not whether it is a problem. The stance marks above are the ratings; these are not.

• fragrance materialLAVANDULA ANGUSTIFOLIA OIL, LINALOOL, CITRAL, LIMONENE

  • LAVANDULA ANGUSTIFOLIA OIL: An essential oil the EU names on its own account as a fragrance substance to be declared on the label, under a shared name covering several lavender species. EU Regulation (EC) 1223/2009, Annex III entry 360, inserted by Commission Regulation (EU) 2023/1545: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products. It is declarable in its OWN right, not by way of any component it carries. The entry is a GROUPED one covering the oils and extracts of Lavandula angustifolia, Lavandula intermedia and Lavandula hybrida, about eight glossary names in all, all declared under the single common name "Lavandula Oil/ Extract", so that name on a label does not identify which of them is present. The duty applies now. Transition footnote (40) lets stock that does not comply, lawfully placed on the Union market before the 31 July 2026 cut-off, be made available until 31 July 2028.
  • LINALOOL: A floral fragrance component named separately on the label. EU Regulation (EC) 1223/2009, Annex III entry 84: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk.
  • CITRAL: A lemon-scented fragrance component named separately on the label; the one name covers three related substances. EU Regulation (EC) 1223/2009, Annex III entry 70: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk. As replaced by Commission Regulation (EU) 2026/909 of 27 April 2026, the entry is a GROUPED one covering citral, geranial and neral, declared collectively as "Citral", with per-product-type caps from 0,032% in deodorant to 1,2% in rinse-off and leave-on hair products. Its three substances carry two different sell-through dates: products not complying may not be placed on the Union market from 1 January 2027 in every case, and may not be made available from 1 July 2028 for citral, footnote (**), or from 1 August 2028 for geranial and neral, footnote (***). In the consolidated text those two footnotes are renumbered (46) and (47); both are worded "these substances", where the footnotes that attach to a single named substance say "that substance".
  • LIMONENE: A citrus-smelling fragrance component named separately on the label; the one name covers three related isomers. EU Regulation (EC) 1223/2009, Annex III entry 88: a fragrance substance whose presence must be indicated in the list of ingredients above 0,001% in leave-on and 0,01% in rinse-off products, because of established contact-allergy risk. That entry carries transition footnote (37): stock that does not comply, lawfully placed on the Union market before the 31 July 2026 cut-off, may still be made available until 31 July 2028. It is marked on the racemic dl-limonene/Dipentene line and the (S)-(l-limonene) line, but NOT the (R)-p-mentha-1,8-diene (d-limonene) line, CAS 5989-27-5, whose duty was already running as entry 88 before Commission Regulation (EU) 2023/1545 and so needed no transition. All three isomers are declared under the single glossary name "Limonene", so that name on a label does not identify which of them is present.

• humectantGlycerin, SODIUM HYALURONATE

  • Glycerin: A humectant, and one of the two ingredients a comparison of moisturiser components found made a significant difference to skin hydration. FDA OTC skin protectant monograph, 21 CFR 347.10(h), lists glycerin as a skin protectant at 20 to 45%. On the humectant half: Jeong CB, Han JY, Cho JC, Suh KD, Nam GW, "Analysis of electrical property changes of skin by oil-in-water emulsion components", Int J Cosmet Sci 2013;35(4):402-410, DOI 10.1111/ics.12059, PMID 23621673, found that "glycerine and urea showed significant skin hydration effects compared with other humectants".
  • SODIUM HYALURONATE: A humectant that holds a large amount of water at the skin surface. Chylińska N, Maciejczyk M, "Hyaluronic Acid and Skin: Its Role in Aging and Wound-Healing Processes", Gels 2025;11(4):281, DOI 10.3390/gels11040281, PMID 40277717, open access: hyaluronic acid's "high osmotic activity and anionic structure enable it to bind large amounts of water", and "sodium and potassium hyaluronate are widely used in moisturizing products". The same review notes that high-molecular-weight hyaluronic acid does not penetrate the deeper layers.

• barrier lipidCHOLESTEROL, CERAMIDE NP

  • CHOLESTEROL: One of the three lipid classes that make up the skin barrier, alongside ceramides and fatty acids. Feingold KR and Elias PM, J Lipid Res 2024, open access: the barrier lipid matrix "by weight is approximately 50% ceramides, 25% cholesterol, and 15% free fatty acids". Corroborated by Wertz PW, "Roles of Lipids in the Permeability Barriers of Skin and Oral Mucosa", Int J Mol Sci 2021;22(10):5229, DOI 10.3390/ijms22105229, PMID 34063352.
  • CERAMIDE NP: One of the lipid families the skin barrier is actually built from. Feingold KR and Elias PM, "The role of ceramides in the disruption of the cutaneous permeability barrier, a common manifestation of skin disorders", J Lipid Res 2024;65(8):100593, DOI 10.1016/j.jlr.2024.100593, open access: the barrier lipid matrix "by weight is approximately 50% ceramides, 25% cholesterol, and 15% free fatty acids".

• soothingNIACINAMIDE

  • NIACINAMIDE: A vitamin B3 form that supports the skin barrier and has anti-inflammatory activity; it turns up in products aimed at acne, rosacea and eczema. Camillo L, Zavattaro E, Savoia P, "Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond", Medicina (Kaunas) 2025;61(2):254, DOI 10.3390/medicina61020254, PMID 40005371, open access: it "is extensively used in ... the treatment of dermatological conditions such as blistering diseases, atopic dermatitis, rosacea, and acne vulgaris", and contributes to reducing inflammation. On the acne evidence specifically: Liu H, Yu H, Xia J, Liu L, Liu GJ, Sang H, Peinemann F, "Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne", Cochrane Database Syst Rev 2020;5:CD011368, DOI 10.1002/14651858.CD011368.pub2, PMID 32356369, records "low-quality evidence" for every nicotinamide comparison it could pool, and none of its four nicotinamide studies measured the physician global assessment at all.